Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY21 Earnings Presentation
22 slides from Dr. Lal Pathlabs's earnings presentation, Jul 31, 2020
Slide 1: Exchange filing cover letter for Q1 FY21 earnings presentation
July 31, 2020 National Stock Exchange of India Bombay Stock Exchange Limited Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Sandra Kurla Complex Sandra (E) Dalal Street Mumbai -400 051. Mumbai- 400001 Subject: Investors Presentation on Unau
Slide 2: Dr. Lal PathLabs Limited Q1 FY21 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q1 FY21 Results Presentation July 31, 2020
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q1 FY21 Snapshot
Q1 FY21 Snapshot* Normalised Revenue PAT EBITDA INR 266.0 Cr INR 54.0 Cr INR 28.4 Cr Patients Samples Tested Processed ~ 3.5 mn 7.9 mn ~ * Q1 results have been adversely impacted due to COVID-19 pandemic and subsequent lockdown 3
Slide 5: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 5 Overview of Dr. Lal PathLabs 6 Key Performance Highlights 8 Financials 9 Financial Highlights 10 Operating Highlights 12 Management Commentary 13 Vibrant Outlook 14 Corporate Overview 16 Shareholding 20 Contact Us 21 DISCLAIMER: This presentation ma
Slide 6: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 12% 15% Zero Professionally managed operations; 7 decades of experience in the world of NO. 1 3 Year Revenue 3-Year PAT Net Debt BRANDED diagnostics CAGR CAGR NATIONAL 60% Well diversified outside home market of ‘Delhi NCR’ DIAGNOSTICS ~67% CHAIN WITH Revenue Contribut
Slide 7: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established brand Pan-India integrated Varied Offerings Unique and successful coverage operating model 216 clinical labs (including National Reference Lab at Catalogue of 455 test panels, Scalable model integrated Established consumer Delhi and Regional Reference 2,537 p
Slide 8: Q1 FY21 Monthly Trends
Q1 FY21 Monthly Trends Revenues (in Rs. crore) Patients Tested (in million) • Performance was impacted in April and May -61% -12% +14% -62% -25% +3% 2020 due to extended lockdowns caused by 114 123 1.6 1.7 1.6 1.7 COVID-19 pandemic 113 108 99 1.2 • Business momentum improved from June 2020 onwards b
Slide 9: Key Performance Highlights
Key Performance Highlights During Q1 FY21: • Revenues decreased by 20.6% Y-o-Y at Rs. 266 crore • Patient volumes declined by 28.4% Y-o-Y at 3.5 million • Normalised EBITDA (after eliminating the impact of stock based compensation & CSR) came in at Rs. 54 crore • Profit After Tax stood at Rs. 28.4 c
Slide 10: Financials
Financials Particulars (Rs. Cr.) Q1 FY21 Q1 FY20 Growth % FY20 Total Revenue 266.0 335.2 -20.6% 1330.4 Total Expenditure 217.6 240.1 986.8 EBITDA 48.4 95.1 -49.1% 343.6 Adj for Stock based comp. & CSR Cost 5.6 3.9 22.0 Normalised operating EBITDA 54.0 99.0 -45.5% 365.6 Normalised Margins 20.3% 29.5%
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Crore 335.2 • Revenue declined in Q1 FY21 by 20.6% to Rs. 266.0 crore. This was due to : 266.0 – Volumes which declined by 28.4% and – Decline in tests per patient from 2.42 to 2.27 Revenue • Realisation per patient in Q1 FY21 came in at Rs. 760, higher as com
Slide 12: Financial Highlights
Financial Highlights All figures in Rs. Crore 89.4 • PBT for Q1 FY21 came in at Rs. 38.1 crore vs. Rs. 89.4 crore in the corresponding quarter of last year, representing a decline of 57.4% 38.1 PBT • Q1 FY21 PBT margin stood at 14.3%, as against 26.7% in the same period of last year Q1 FY20 Q1 FY21
Slide 13: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 216 3,095 6,995 193 200 2,569 6,426 2,153 5,624 FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20 No. of Patients (Mn) No. of Samples (Mn) 19.4 47.7 17.6 41.8 15.2 34.7 3.5 7.9 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 12
Slide 14: Management Commentary
Management Commentary Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman “This was a difficult quarter, not just for Dr. Lal Pathlabs, but for the entire nation and the economy. Business was impacted adversely, with volumes getting hit. However, we are confident
Slide 15: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Kolkata National Laboratory and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities North, East & Central Indian of the markets industry Higher co
Slide 16: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Logistics Lab Operations Business Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients
Slide 17: Corporate Overview
Corporate Overview DLPL Strategy for future growth Experienced Management team 16
Slide 18: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations 4 3 Expand management of Geographic hospital based expansion and clinical laboratories 17
Slide 19: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city approach standards diagnostic testing in
Slide 20: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Company Sec
Slide 21: Shareholding as of 30th June, 2020
Shareholding as of 30th June, 2020 20.0% FIIs 14.7% 56.3% Others Promoter and Promoter Group 9.0% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 20
Slide 22: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests